Roche
Half year 2008

July 2008
Basel, London, New York

This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others:

1 pricing and product initiatives of competitors;
2 legislative and regulatory developments and economic conditions;
3 delay or inability in obtaining regulatory approvals or bringing products to market;
4 fluctuations in currency exchange rates and general financial market conditions;
5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products;
6 increased government pricing pressures;
7 interruptions in production
8 loss of or inability to obtain adequate protection for intellectual property rights;
9 litigation;
10 loss of key executives or other employees; and
11 adverse publicity and news coverage.

Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche’s earnings or earnings per share for this year or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche.

For marketed products discussed in this presentation, please see full prescribing information on our website – www.roche.com

All mentioned trademarks are legally protected

Group

Severin Schwan
Chief Executive Officer

H1 2008: Industry-leading sales performance in our markets

CHF bn	H1'07	H1'08	% change in CHF	% change in local	USD growth
Pharmaceuticals	18.3	17.3	-6	3	10
excl. Tamiflu pandemic	17.1	17.2	1	9	18
Diagnostics	4.6	4.7	4	11	22
Roche Group	22.8	22.0	-4	4	13
excl. Tamiflu pandemic	21.6	21.9	1	10	18

H1 2008: CHF 2 billion organic sales growth



H1 2008: Profit maintained despite CHF 3 billion Tamiflu and currency headwind

CHF billion	H1'07	H1'08	Change CHF billion	%	loc %
Sales	**22.8**	**22.0**	**-0.8**	**-4**	**+4**
Operating profit before ex. items	**7.5**	**7.0**	**-0.5**	**-6**	**+2**
as % of sales	***32.8***	***32.0***			
Operating profit	**7.5**	**7.4**	**-0.1**	**-2**	**+7**
as % of sales	***32.8***	***33.4***			
Net income	**5.9**	**5.7**	**-0.1**	**-2**	
as % of sales	***25.7***	***26.0***			
Core EPS	**5.95**	**5.75**		**-3**	**+3**

Reconfirming objectives for 2008

Sales

- High single digit local currency sales increase for Roche Group (excl. Tamiflu pandemic[1])
- Above-market sales growth[1] in both divisions

Core EPS

- Core earnings per share target[2] at least at record 2007 level despite significant increase in R&D investment and considerably lower Tamiflu pandemic sales

Shareholder return

- Continuous increase in dividend pay-out ratio over the next 3 years

Barring unforeseen events

---

[1] Excluding government and corporate stockpiling orders of Tamiflu for pandemic use
[2] At constant exchange rates

Pharmaceuticals Division

William M. Burns
CEO Roche Pharmaceuticals



H1 2008: Highlights in Pharma

Strong momentum continues

Positive underlying performance

- Sales growing more than twice the world market[1]
- Operating profit margin improved by almost 2% pts while investing in the future

Further strengthening the pipeline

- Major phase III decisions in Metabolics taken (CETPi and GLP-1)
- Phase II opt-in in CNS (Memory)
- Acquisitions: Piramed (PI3-kinase targeting)
- Licensing deal: ThromboGenics / BioInvent: MAb blocking placental growth factor (PlGF) - potential new cancer target

---

[1] Excluding government and corporate stockpiling orders of Tamiflu for pandemic use

---

Pharma: Sales growth more than twice global market

Sales CHF m	H1'07	H1'08	% change in CHF	% change in local	USD growth
Roche Pharma	11,367	10,938	-4	2	12
excl. Tamiflu pandemic	10,354	10,845	5	11	22
Genentech	5,227	4,867	-7	9	9
Chugai	1,674	1,452	-13	-11	1
excl. Tamiflu pandemic	1,481	1,450	-2	0	15
Pharmaceuticals	**18,268**	**17,257**	**-6**	**3**	**10**
excl. Tamiflu pandemic	**17,062**	**17,162**	**1**	**9**	**18**

Continued double-digit growth driven by Roche Pharma

	2007 vs. 2006[1]				2008 vs. 2007[1]		USD growth	
	Q1	Q2	Q3	Q4	Q1	Q2	Q1	Q2
Pharmaceuticals Division	**20**	**16**	**6**	**5**	**1**	**5**	**8**	**13**
excl. Tamiflu pandemic[2]	**16**	**14**	**12**	**11**	**9**	**10**	**17**	**18**
Roche Pharma	18	13	1	7	1	3	11	14
excl. Tamiflu pandemic[2]	13	11	10	14	11	11	22	23
Genentech	30	26	18	6	9	9	9	9
Chugai	11	2	8	-8	-23	2	-13	18
excl. Tamiflu pandemic[2]	-7	4	4	4	-2	2	11	18

---

[1] Local Currency
[2] Tamiflu corporate and government pandemic sales; all figures in %.

H1 2008: Strong Pharma operating performance

Efficiency gains in manufacturing and marketing

	H1'08 CHF million	% sales	H1'08 vs. H1'07 in CHF m
Sales	**17,257**	**100.0**	**-1,011**
Royalties & other op inc	**1,059**	**6.1**	**-11**
Cost of sales	**-4,219**	**-24.4**	**+609**
M & D	**-3,164**	**-18.3**	**+305**
R & D	**-3,670**	**-21.3**	**-13**
G & A	**-670**	**-3.9**	**+74**
Operating profit before except. items	**6,593**	**38.2**	**-47**

H1'08 vs. H1'07 Local growth



Improving efficiency, investing in R&D

H1 2008: Strong improvement in operating margin[1] carried by Roche Pharma



[1] before exceptional items [2] at constant exchange rates

Pharma: Continued substantial margin improvement

Pharma operating profit[1] (CHF billion)



[1] Continuing businesses, before exceptional items, not always directly comparable

Therapeutic areas: quarter review

2008 objectives

Oncology: Europe/RoW growing strongly



Oncology: Key brands on double-digit growth path

Major brands (CHF bn) **H1 '08 vs. H1 '07 local growth**



Growth driven by increased adoption in iNHL maintenance (US, EU), NHL induction (ex-US) and in RA

Market penetration in adj BC continues to increase, stable in mBC

78% growth in EU/RoW driven by label expansions (mCRC, mBC, mNSCLC, mRCC)

Continued strong growth in EU/RoW (+34%), solid launch in Japan

mCRC label expanded in EU

Oncology: H1 2008 pipeline update

Major newsflow expected in H2 2008

MabThera in relapsed CLL: REACH

Randomized ph. III, 552 patients
Fludarabine+cyclophosphamide
+/-MabThera

Expect data in H2 '08

Avastin in 1st line mBC: RIBBON-1

Phase III study, 1200 patients, 2 analyses:
Anthracycline-/taxane-based +/- Avastin, and Xeloda +/- Avastin

Expect topline data H2 '08

Tarceva+Avastin in 2nd line NSCLC: BETA lung

Tarceva+/-Avastin
Enrollment completed Q2 '08
Potentially label-enabling for Avastin

Expect topline data H2 '08

Tarceva 1st line maintenance NSCLC: SATURN

4 chemo cycles followed by T vs. placebo
Enrollment completed Q2 '08
Potentially label-enabling for Tarceva

Expect topline data H2 '08

Inflammation/Autoimmune/Transplantation

Building in rheumatoid arthritis

CHF bn (as reported)

H1 ’08 vs. H1 ’07 local growth



H1 2008

CellCept

- Double-digit growth continues

MabThera/Rituxan in RA

- Market penetration in RA continues to increase strongly

Actemra

- Actemra approved for RA and JIA in Japan
- AMBITION and RADIATE data at EULAR, LITHE met 1 yr primary end point
- FDA Ad Com panel on July 29th 2008

Autoimmune: H1 2008 pipeline update

Ocrelizumab moves forward in RRMS

MabThera RA: DMARD IR signs and symptoms (SERENE)

Primary endpoint met; to be filed in 2009 together with X-ray data (IMAGE)

Filing 2009

SLE: endpoint not met

EXPLORER (MabThera): endpoint not met
BEGIN (ocrelizumab): study discontinued

Program discontinued

Lupus nephritis: studies with MabThera and ocrelizumab ongoing

LUNAR (MabThera): phase III ongoing

BELONG (ocrelizumab):
enrolment started in Q1 2008

LUNAR: results in early 2009

Ocrelizumab: RRMS

Excellent proof-of-concept data for MabThera in RRMS - ocrelizumab to be developed in RRMS

Phase II dose-finding study initiated

Phase II initiated

Metabolism/Bone/Anemia

Boniva continues to gain market share

Major brands (CHF m)

H1 '08 vs. H1 '07
local growth



Bonviva/ Boniva	TRx level maintained in US in spite of recent generic entry; successful uptake in Europe
Xenical	Decline as expected due to switch to OTC version
NeoRecormon/ Epogin	NeoRecormon: -10% in spite of price pressure and biosimilars in EU/RoW. Epogin: -23% due to continued price pressure in Japan.

Metabolism: H1 2008 pipeline update

CETPi and GLP-1 on track; DPP-IV to be out-licensed

CETPi (R1658): M&M study to prove the concept

Safety and tolerability data well received at ACC '08

Phase III recruiting

GLP-1 (R1583): potential for best-in-class product

Phase II data encouraging – presented at ADA '08

Phase III decided

DPP-IV (R1579)

Phase II data available

Efficacious but no evidence of weight loss
Good safety profile

Out-licensing planned

PPAR $\alpha\gamma$ (R1439)

Initial phase II data available
Renal study ongoing - data by year end

Looking for a safe and differentiated profile

Go/no-go decision by early '09

Virology: Pegasys back to moderate growth

Substantially less Tamiflu pandemic sales

Major brands (CHF bn) **H1 '08 vs. H1 '07 local growth**



Tamiflu quarterly sales (CHF m)



	H1 '07	H1 '08
Seasonal	110	232
Pandemic[1]	1,206	95

---

[1] Governmental & Corporate

Therapeutic areas: quarter review

2008 objectives

Pharmaceuticals objectives for 2008

Rich clinical newsflow ahead

Major clinical data

Compound	Phase	Indication / data	Timing	Status H1
Avastin	III	mBC (AVADO)	H1 2008	✓
Avastin	III	mBC (RIBBON-1)	H2 2008	
Avastin+Tarceva	III	2nd line NSCLC (BETA lung)	H2 2008	
Tarceva	III	1st line NSCLC (SATURN)	H2 2008	
MabThera	III	RA, DMARD-IR	Q1 2008	✓
MabThera	III	SLE (EXPLORER)	Q2 2008	Endpoint not met
MabThera	III	PPMS (OLYPMUS)	Q2 2008	Endpoint not met
MabThera	III	CLL 1st line ph. III data interim	Q1 2008	✓
MabThera	III	CLL relapsed ph. III data	H2 2008	
Xeloda	III	Adjuvant CC (NO16968) interim	Event-driven	
Actemra	III	RA (AMBITION, RADIATE) full data	H1 2008	✓
GLP-1	IIb	Type 2 diabetes full data	H1 2008	✓
DPP-IV	II	Type 2 diabetes	H2 2008	✓ (outlicensing)

Filings

Compound	Indication	Status
Avastin	mBC (AVADO)	
Avastin+Tarceva	NSCLC 2nd line (BETA lung)	
MabThera	CLL	
MabThera	RA, DMARD IR	To be filed in 2009
Avastin	Glioblastoma 2nd line	To be filed Q4 2008

Divisional sales growth

Above-market excluding pandemic Tamiflu

barring unforeseen events

Diagnostics Division

Jürgen Schwiezer

CEO Roche Diagnostics

H1 2008: Highlights in Diagnostics Division

Extending global market leadership

Strong top-line growth in all regions

- Above market growth at 11% (local currencies)
- Operating profit impacted by strategic investments
- Diabetes Care returned to growth (Q2: +7% global, +9% US)

New products & instrument placements driving market share gains

- Six new Immunochemistry tests launched
- Genome FLX sequencing systems advanced three times the market
- Ventana integration on track, continues to outperform competition

Diagnostics Event at AACC, Washington DC, USA
July 28th, 2008

H1 2008: Sales by business area

Strong growth in Professional Diagnostics & Applied Science

Sales CHF m	H1 '07	H1 '08	% change in CHF	% change in local	USD growth %
Professional Diagnostics	2,110	2,183	3	9	21
Diabetes Care	1,544	1,482	-4	2	12
Molecular Diagnostics	574	551	-4	4	12
Applied Science	331	367	11	21	29
Tissue Diagnostics[1]	-	164	-	-	-
Diagnostics Division	**4,559**	**4,747**	**4**	**11**	**22**

---

[1] Sales from beginning of February 2008

H1 2008: Near-term operating profit impacted by acquisitions and investments into future growth drivers



Impact recent acquisitions (Ventana, BioVeris, NimbleGen, 454 Lifescience)
- Investments to develop acquired businesses
- Amortisation intangible assets
- One-time charges
  - Write-off of fair-value write-up of Ventana's inventory
  - Transaction and integration costs

Investments in ongoing business
- Over-proportionate spend sales force & instr. placements
  - Accu-Chek meters, cobas 6000 analysers, CAP/CTM
- Strong competition in US diabetes care market
- Accelerated R&D spend
  - New products in Diabetes Care & Molecular Dia
- Portfolio mix effects

Improvement expected H2

H1 2008: Strategic investments impacting P&L

	H1'08 CHF million	H1'08 % sales	H1'08 vs. H1'07 in CHF m
Sales	4,747	100.0	+188
Royalties & other op inc	77	1.6	-11
Cost of sales	-2,313	-48.7	-321
M & D	-1,207	-25.5	-117
R & D	-437	-9.2	-77
G & A	-286	-6.0	-30
Operating profit	581	12.2	-368

H1'08 vs. H1'07 Local growth



H1 2008: New products and instrument placements driving growth



Immunochemistry continued double-digit growth in all regions; Six new immunoassays launched

North America Q2 sales grew strongly (+9%) following weak Q1; Accu-Chek Aviva main growth driver

New HPV study initiated to support FDA registration; Exclusive agreement DxS for KRAS & EGFR tests

Strong growth in sequencing (+102%); Expanded microarray menu

Continued strong growth in Advanced Staining; new systems launched to further drive sales

---

Key growth drivers in 2008

Commercialise current assets; prepare market for new drivers

	Key 2007 Launches	Key 2008 Launches*
Professional Diagnostics	• cobas 4000 analyser series – cobas e 411 analyser • cobas IT 3000 & 1000 • cobas h 232 • cobas h 152 (Accutrend Plus)	• cobas 4000 analyser series – cobas c 311 analyzer • Accu-Chek Inform II • menu: HCV, RA, sepsis, CMV ✓
Diabetes Care	• Accu-Chek Performa • Accu-Chek Compact Plus (new) • Accu-Chek 360⁰	• Accu-Chek Aviva Nano • Accu-Chek Active (new)
Molecular Diagnostics	• cobas s 201 system & WNV Test (US) • Cobas AmpliPrep/Cobas TaqMan HIV Test (US)	• CAP/CTM HCV Test (US) • cobas TaqScreen MPX (US) (J) ✓ • cobas TaqMan 48 HBV Test (US) ✓ • cobas TaqMan 48 CT Test (EU)
Tissue Diagnostics	• PATHWAY HER-2 Primary Antibody • INFORM *HER2* DNA Probe Assay SISH (EU)	• BenchMark Ultra IHC/ISH staining system • Vantage Workflow Management Solution ✓ • VIAS: Imaging application for *HER-2* SISH (EU) ✓
Applied Science	• Genome Sequencer FLX	• Real-Time Cell Analyser xCELLigence • XLR-HD for DNA sequencing (454) • Comprehensive menu of NimbleGen microarrays ✓

Divisional sales growth outlook	**Above market growth in local currencies**

barring unforeseen events

---

* Subject to appropriate regulatory approvals; US launch may be later

Group financial results

Dr. Erich Hunziker
Chief Financial Officer

H1 2008: Highlights

- Core EPS in line with sales performance, despite CHF 3 billion lower sales due to Tamiflu pandemic and a strong CHF
- Tax rate reduced
- Lower net cash position due to payment of dividends, Ventana acquisition and increase in ownership in Chugai
- Strong financial condition

H1 2008: Group operating performance

Increase in operating profit¹ (in LC) in spite of substantial R&D growth and lower Tamiflu pandemic sales

	H1'08		H1'08 vs. H1'07
	CHF million	% sales	in CHF m
Sales	**22,004**	**100.0**	**-823**
Royalties & other op inc	**1,136**	**5.2**	**-22**
Cost of sales	**-6,532**	**-29.7**	**+288**
M & D	**-4,371**	**-19.9**	**+188**
R & D	**-4,107**	**-18.7**	**-90**
G & A	**-1,089**	**-4.9**	**+23**
Operating profit¹	**7,041**	**32.0**	**-436**



---

[1] before exceptional items

H1 2008: Group results

Operational excellence translated into the bottom line

CHF million	2007	2008	% change CHF	% change local
Sales	22,827	**22,004**	**-4**	**+4**
Operating free cash flow	5,365	**4,806**	**-10**	**-2**
% of sales	*23.5*	*21.8*		
Operating profit before exceptional items	7,477	**7,041**	**-6**	**+2**
% of sales	*32.8*	***32.0***		
Net financial result	500	**237**	**-53**	
Taxes	-2,115	**-1,861**	**-12**	
Tax rate in %	*26.5*	***24.5***		
Net income	5,862	**5,732**	**-2**	
% of sales	*25.7*	***26.0***		
Core EPS (CHF)	5.95	**5.75**	**-3**	**+3**

H1 2008: Group tax rate

Substantial decrease due to Roche tax rate



Free cash flow and Net cash H1 2008

Dividends and tax payments drive Free Cash Flow.
Substantial impact from acquisitions on net cash



Net cash 30 June 2008

Dividends, tax payments drive Free Cash Flow

CHF million	31 December 2007				30 June 2008			
	Roche	GNE	Chu	Total	Roche	GNE	Chu	Total
Cash & cash equivalents	1,869	1,157	729	3,755	1,229	2,141	687	4,057
Marketable securities	14,496	5,209	742	20,447	6,990	3,929	729	11,648
Liquid funds	16,365	6,366	1,471	24,202	8,219	6,070	1,416	15,705
Long-term debt	-1,270	-2,564	-	-3,834	-1,150	-2,532	-	-3,682
Short-term debt	-2,357	-675	-	-3,032	-1,298	-610	-	-1,908
Interest-bearing liabilities	-3,627	-3,239	-	-6,866	-2,448	-3,142	-	-5,590
Net cash	12,738	3,127	1,471	17,336	5,771	2,928	1,416	10,115

Net change in net cash				
	Roche	CHF	-6,967 m	**Group CHF -7,221 m**
	Genentech	CHF	-199 m	
	Chugai	CHF	-55 m	

Our objectives for 2008

Sales

- High single digit local currency sales increase for Roche Group (excl. Tamiflu pandemic[1])
- Above-market sales growth[1] in both divisions

Core EPS

- Core earnings per share target[2] at least at record 2007 level despite significant increase in R&D investment and considerably lower Tamiflu pandemic sales

Shareholder return

- Continuous increase in dividend pay-out ratio over the next 3 years

Barring unforeseen events

[1] Excluding government and corporate stockpiling orders of Tamiflu for pandemic use
[2] At constant exchange rates

Pharma sales H1 2008 (vs. 2007)

Top 20 products growing by 14% excl. Tamiflu pandemic

	Global		US		Japan		Europe/RoW	
	CHF m	% loc	CHF m	% loc	CHF m	% loc	CHF m	% loc
MabThera/Rituxan	2,867	17	1,381	13	95	12	1,391	21
Herceptin	2,474	11	712	6	98	23	1,664	14
Avastin	2,351	36	1,313	14	71	2597	967	78
CellCept	1,010	13	458	15	19	17	533	12
NeoRecorm/Epogin	892	-14	-	-	217	-23	675	-10
Pegasys	785	3	176	-2	41	71	568	3
Tarceva	587	28	242	13	20	-	325	34
Xeloda	573	14	186	10	20	62	367	14
Bonviva/Boniva	507	51	312	43	-	-	195	68
Lucentis	440	-2	440	-2	-	-	-	-
Tamiflu	327	-71	264	-34	16	-93	47	-92
Xenical	264	-16	26	-40	-	-	238	-12
Valcyte/Cymevene	261	10	116	8	-	-	145	12
Xolair	259	7	259	7	-	-	-	-
Pulmozyme	237	13	126	12	-	-	111	15
Nutropin	195	-5	188	-5	-	-	7	-7
Neutrogin	192	1	-	-	192	1	-	-
Rocephin	176	-9	4	-62	28	3	144	-6
Activase/TNKase	164	-7	142	-9	-	-	22	13
Madopar	154	5	-	-	9	5	145	5

Pharma local sales growth[1] in %

Global top 20 products

	Q2/07	Q3/07	Q4/07	Q1/08	Q2/08
MabThera/Rituxan	16	17	12	17	16
Herceptin	25	18	14	11	12
Avastin	39	45	41	35	38
CellCept	14	4	16	11	16
NeoRecormon/Epogin	-5	-5	-15	-13	-14
Pegasys	7	7	14	-3	10
Tarceva	31	28	24	28	27
Xeloda	18	20	22	13	14
Bonviva/Boniva	123	62	63	56	47
Lucentis	1964	31	-9	-5	2
Tamiflu	25	-60	-46	-64	-86
Xenical	-6	-9	-17	-11	-21
Valcyte/Cymevene	19	9	7	9	10
Xolair	13	11	2	6	7
Pulmozyme	15	14	13	15	11
Nutropin	-2	3	-8	-5	-5
Neutrogin	12	15	14	1	1
Rocephin	-2	-2	-4	-4	-13
Activase/TNKase	20	6	-2	-3	-11
Madopar	6	5	14	0	9

[1] versus previous year

Pharma local sales growth in %

Top 20 products by region

	US				Japan				Europe/RoW			
	Q3[1]	Q4[1]	Q1[2]	Q2[2]	Q3[1]	Q4[1]	Q1[2]	Q2[2]	Q3[1]	Q4[1]	Q1[2]	Q2[2]
MabThera/Rituxan	14	4	14	13	4	2	13	11	23	25	21	21
Herceptin	6	1	9	3	3	0	16	29	26	23	12	15
Avastin	37	23	13	15	-	-	-	1567	59	80	78	78
CellCept	-1	17	14	15	14	18	13	21	9	14	8	16
NeoRecorm/Epogin	-	-	-	-	-12	-22	-16	-29	-2	-11	-13	-7
Pegasys	-27	-3	-10	5	34	53	98	53	22	20	-4	9
Tarceva	1	5	10	17	-	-	-	-	68	47	40	28
Xeloda	30	19	16	5	11	14	48	73	15	25	11	18
Bonviva/Boniva	27	40	47	39	-	-	-	-	278	160	77	61
Lucentis	31	-9	-5	2	-	-	-	-	-	-	-	-
Tamiflu	-71	52	83	-87	48	-58	-93	-78	-70	-92	-94	-83
Xenical	-30	-46	-35	-46	-	-	-	-	-5	-11	-7	-17
Valcyte/Cymevene	4	3	11	5	-	-	-	-	15	11	8	16
Xolair	11	2	6	7	-	-	-	-	-	-	-	-
Pulmozyme	14	10	10	14	-	-	-	-	14	17	22	8
Nutropin	3	-8	-6	-4	-	-	-	-	-7	-10	-1	-12
Neutrogin	-	-	-	-	15	14	1	1	-	-	-	-
Rocephin	-13	-32	-34	-85	11	-1	9	-2	-4	-3	-3	-9
Activase/TNKase	6	0	-6	-12	-	-	-	-	1	-16	30	1
Madopar	-	-	-	-	2	3	5	5	5	15	0	9

[1] 2007 vs. 2006

[2] 2008 vs. 2007

Pharma sales H1 2008 (vs. 2007)

Other launches since January 2003[1]

	Global		US		Japan		Europe/RoW	
	CHF m	% loc	CHF m	% loc	CHF m	% loc	CHF m	% loc
Copegus	119	6	3	8	18	212	98	-6
Fuzeon	85	-40	32	-47	-	-	53	-34
Evista	76	4	-	-	76	4	-	-
Raptiva	64	9	64	9	-	-	-	-
Renagel	31	11	-	-	31	11	-	-
Mircera	15	-	-	-	-	-	15	-
Femara	7	98	-	-	7	98	-	-
Actemra	7	231	-	-	7	231	-	-

---

[1] other than launches already covered in Top 20

H1 2008: Gaining further market share in all regions

Local sales growth



% Key products of total pharmaceutical sales



CEMAI: Central and Eastern Europe, Middle East, Africa, Indian Subcontinent

H1 2008: Pharmaceuticals Division

Regional sales distribution and growth excluding Tamiflu



all growth figures are in local currencies

CEMAI: Central and Eastern Europe, Middle East, Africa, Indian Subcontinent

---

Metabolism/Bone

Franchise growth driven by Bonviva/Boniva



MabThera/Rituxan

Strong double-digit growth continues in EU/RoW

Global sales



Regional sales **Local growth**



- YTD sales of CHF 2.867 billion
- Continued growth in 1st line aNHL and iNHL in EU/RoW
- Growth from increased usage in iNHL following 1st line (including maintenance therapy) in US and EU
- Penetration of RA market in US and Europe/ ROW continues to increase
- Two year data demonstrating continued inhibition of structural damage in RA patients (TNF-IRs) presented at EULAR 2008

[1] local growth

Herceptin

Adjuvant penetration continues to increase

Global sales



Regional sales **Local growth**



- YTD sales of CHF 2.474 billion
- US market penetration (Q2 '08)
  - adjuvant: approximately 85%, slightly up from approx. 80% (Q4'07)
  - 1st line metastatic: approx. 75%, slightly up from approx. 70% (Q4'07)
- Top 5 EU market penetration (end Q1'08)
  - adjuvant: approx. 75%, slightly up from approx. 70% (Q4'07)
  - 1st line metastatic: approx. 80%, stable

[1] local growth

Avastin

Major label expansions being rolled out

Global sales



Regional sales **Local growth**



Europe/ RoW	+78 %
Japan	+2597 %
US	+14 %

- YTD sales of CHF 2.351 billion
- US:
  - growth mostly from increased use in 1st line mBC (penetration rate: approx. 35%) and 1st line mNSCLC (penetration rate: 65% of eligible patients)
- EU/RoW:
  - strong growth in mCRC continues; 1st line mCRC penetration rate of approx. 25% in top 5 EU, over 30% excluding UK (as of end Q1'08)
  - Continued very successful roll-out in 1st line mBC (25% penetration of on label market in major EU markets); mNSCLC and mRCC launches: early indicators positive

[1] local growth

Tarceva

Ongoing strength in Europe

Global sales



Regional sales **Local growth**



Europe/ RoW	+34 %
Japan	NM
US	+13 %

- YTD sales of CHF 587 million
- Market penetration in NSCLC, top 5 EU (Q1'08):
  - 2nd line: approx. 30%
  - 3rd line: approx. 45%

[1] local growth

Xeloda

Label expansions driving growth

Global sales



Regional sales

Local growth



- YTD sales of CHF 573 million
- Xeloda mCRC broad label extension approval in EU in Q1 2008
- Strong growth in Japan driven by new indications (adjuvant CC and new dosage strength in mBC)

---

[1] local growth

Avastin

Maximizing a key asset in oncology

Main Indication		Study name	Status
mCRC	2nd line, after progression on 1st line Avastin	**ML18147/AIO0504**	Initiated Q1'06
Adjuvant colon cancer	Stage II high risk / stage III	**AVANT**	Recruitment completed Q2'07
	Stage II / stage III	**NSABP C-08**	Next interim analysis Q4 '08 Expect final analysis in 2009
Met. gastric cancer	1st line	**AVAGAST**	Initiated Q3 2007
Renal cell carcinoma	1st line	**AVOREN**	Approved EU; US filing Q3'08
	1st line	**CALGB 90206**	Topline PFS results to be submitted to FDA in Q3'08
Ovarian Cancer	1st line	**GOG-0218**	Initiated Q3'05
	1st line	**ICON-7**	Initiated Q4'06
	Relapsed, platinum-sensitive	**GOG-0213**	Initiated Q4'07
	Relapsed, platinum-sensitive	**OCEANS**	Initiated Q2'07-expanded to phase III study in Q2 '08
Prostate Cancer	1st line, hormone refractory	**CALGB 90401**	enrollment completed Q4 2007 expect data in 2010
Glioblastoma multiforme	relapsed	**BRAIN** (ph. II)	To be submitted in H2 '08
	1st line	**Phase III in preparation**	

Avastin

Maximizing a key asset in oncology

Main Indication		Study name	Status
NSCLC	1st line (with Tarceva)	**ATLAS**	Completed enrollment Q2'08
	2nd line (with Tarceva)	**BETA Lung**	Expect results in H2'08
	1st line squamous	**BRIDGE** (pilot study)	Expect results Q4'08
	1st or 2nd line non-squamous previously treated CNS mets	**PASSPORT**	Expect results late '08/ early '09
Adjuvant NSCLC	Stage IB-IIIA, sq. + non-sq.	**ECOG 1505**	Initiated Q3'07
mBC	1st line HER2-negative	**AVADO**	Filing for approval H2 2008
	1st line HER2-negative	**RIBBON-1**	Top-line data expected H2'08
	2nd line HER2-negative	**RIBBON-2**	Completed enrollment Q2'08 - expect results 2009
	1st line HER2-positive (with Herceptin)	**AVEREL**	Initiated Q3'06
	1st line HER2-positive (with Herceptin)	**E1105**	Initiated Q1'08
Adjuvant BC	HER2-negative	**E5103**	Initiated Q4'07
	HER2-negative, ER-/PR-neg.	**BEATRICE**	Initiated Q4'07
	HER2-positive (with Herceptin)	**BETH**	Initiated Q2'08
NHL aggressive	1st line (with MabThera)	**MAIN**	Initiated in Q3'07

Herceptin, pertuzumab and T-DM1

Moving the standard of care in HER2-positive breast cancer

Main Indication		Study name	Status
HERCEPTIN			
Gastric cancer	Combo with chemotherapy	**ToGA**	Initiated Q3'05, final analysis 2009, event-driven
Adjuvant BC	1 year vs. 2 years treatment	**HERA**	event-driven - Interim analysis 2008/'09 with potential for results on 2 yrs vs 1 yr treatment duration
mBC HER2+	Continuation of Herceptin beyond progression	**GBG26**	Data presented at ASCO 2008
PERTUZUMAB			
mBC HER2+, 1st line	Herceptin+docetaxel+/-p	**CLEOPATRA** (ph. III)	Initiated Q1'08
Early BC HER2+	Combo with Herceptin	**NeoSphere** (ph. II)	Initiated Q1'08
mBC HER2+, Herceptin pretreated	Combo with Herceptin	**BO17929** (ph. II)	Full efficacy data at ASCO '08
TRASTUZUMAB-DM1 (T-DM1)			
mBC, HER2+, 2nd line	Monotherapy	**Genentech study** (ph. II)	Initiated Q3 '07, completed enrollment Q2 '08, expect to submit interim data to ASCO Breast Cancer Symposium, September 2008

Xeloda / Tarceva / MabThera

Expanding to new indications and combinations

Main Indication		Study name	Status
XELODA			
Adjuvant CC	Combo with Avastin	**AVANT**	Recruitment completed Q2'07
	XELOX vs. 5FU/LV	**NO16968**	Recruitment completed, final analysis event driven ('08/'09)
Adjuvant BC	AC -> T vs. AC -> TX	**NO17629**	Recruitment completed in Jan '06, final analysis event driven
TARCEVA			
NSCLC 1st l. maint.	Combo with chemotherapy	**SATURN**	Expect results H2'08
	Combo with Avastin	**ATLAS**	Completed enrollment Q2'08
NSCLC 2nd line	Combo with Avastin	**BETA Lung**	Expect results H2 '08
Adjuvant NSCLC		**RADIANT**	Expect to complete enrollment 2009/2010
MABTHERA			
NHL1st line maint.	After MabThera induction	**PRIMA**	Recruitment completed Q1'07, Final analysis expected H2'10
CLL 1st line	Combo with chemotherapy	**CLL8**	Met primary endpoint-data at ASH 2008
CLL relapsed	Combo with chemotherapy	**REACH**	Recruitment completed Q3'07, data expected H2 '08

Actemra

Broadly investigated in all RA segments

Main Indication		Study name	Status
Rheumatoid Arthritis	MTX–IR	**OPTION**	Presented at EULAR 2007
	DMARD–IR	**TOWARD**	Presented at ACR 2007
	MTX-naive (monotherapy)	**AMBITION**	Presented at EULAR 2008
	Anti-TNF IR	**RADIATE**	Presented at EULAR 2008
	MTX–IR Prevention of structural Damage (X-ray study)	**LITHE**	2 yrs study - 1 yr data submitted to ACR '08

IR = inadequate responders

RA/autoimmune anti-CD20 pipeline

Major rheumatoid arthritis program

Main Indication		Study name	Status
Rheumatoid Arthritis			
MABTHERA	MTX–IR	**SERENE** (ph. III)	Met primary endpoint-submitted to ACR'08
	MTX–IR dose escalation retreatment	**MIRROR** (ph. III)	Recruitment completed, submitted to ACR '08
	Anti-TNF–IR	**SUNRISE** (ph. III)	Submitted to ACR '08
	MTX-naive, X-ray study	**IMAGE** (ph. III)	Expect data late '08/early '09
	Combo with Enbrel	**TAME** (ph. II)	Initiated Q2'06
OCRELIZUMAB	MTX–IR	**STAGE** (ph. III)	Initiated Q4'06-expect data 2010
	Anti-TNF IR	**SCRIPT** (ph. III)	Initiated Q2'07-expect data 2010
	MTX–naive; X-ray study	**FILM** (ph. III)	Initiated Q2'07

IR = inadequate responders

RA/autoimmune anti-CD20 pipeline

Ocrelizumab to be developed for multiple sclerosis

Main Indication		Study name	Status
Multiple Sclerosis			
MABTHERA	RRMS	**HERMES**	Met primary endpoint, data presented at AAN 2007
OCRELIZUMAB	RRMS	**Phase II**	Initiated July '08
Anca ass. vasculitis			
MABTHERA		**RAVE**	Initiated Q4'04
Lupus nephritis			
MABTHERA		**LUNAR** (ph. III)	Expect data H1'09
OCRELIZUMAB		**BELONG** (ph. III)	Initiated Q1'08

Metabolism/type 2 diabetes

Major decision points in 2008

Main Indication		Status
Type 2 Diabetes		
R1583 (GLP-1)	Decided to move into Phase III	Phase II data presented at ADA 2008
R1439 (PPAR αγ)	Phase II	Phase III decision expected by early 2009
R1579 (DPP IV-3)	Phase II	Outlicensing planned
R1511 (GK 3)	Phase I	Ongoing
Dyslipidemia		
R1658 (JTT-705)	Phase III recruiting	Phase II safety data presented at ACC 2008

Roche R&D pipeline today



phase I - (41 NMEs + 1 AI)

R547	solid tumors
R1530	solid tumors
R1602	solid tumors
R4733	solid tumors
R7160	solid tumors
R7167	solid tumors
R7334	solid tumors
R7112	oncology
R7159	NHL
R7204	malignant melanoma
GEN	anti-cMET – cancer therapy
GEN	anti-CD20 3rd gen. – hem. malig.
GEN	IAP ant. – cancer therapy
GEN	MEK inh. – cancer therapy
GEN	ABT-263–solid tumors & hem. malig.
GEN	PI3 kinase inhibitor – cancer therapy
GEN	CD40 Ab – NHL/MM/rel.large B-CL
CHU	CRC
R1646	pain
R1671	asthma
R3477	autoimmune diseases
R4930	OX40L - asthma
R7103	COPD
R7277	RA
GEN	IFN-alpha Ab - SLE
GEN	Anti-IL 13 - asthma
BTI	VAP-1 – inflammatory diseases
R7128	HCV
R7227	HCV
CHU	HCV
R1511	type 2 diabetes
R7089	type 2 diabetes
R1512	PVD
R1663	anticoagulant
R4929	type 2 diabetes
R7201	type 2 diabetes
R7232	dyslipidemia
R7234	type 2 diabetes
GEN	Anti-oxLDL sec. prev CV events
R1295	MS
R1450	Alzheimer's
R4996	Alzheimer's

phase II - (18 NMEs + 11 AIs)

R435	**Avastin** - glioblastoma
R435	**Avastin** - NSCLC squamous
R435	**Avastin** - NSCLC mCNS treat.
R1273	**pertuzumab** – EBC HER2+
R1273	**pertuzumab** – ovarian cancer
R1415+R435	**Tarceva + Avastin** – NSCLC 1st line
R1507	Ewing's sarcoma
R3502	T-DM1 - mBC
GEN	CD40 Ab – diff. large B Cell lymph.
GEN	Apomab - cancer
GEN	Apo2L/TRAIL - cancer
GEN	ABT-869 – solid tumors
GEN	**Avastin** – extensive SCLC
GEN	**Avastin** - relapsed MM
GEN	Hedgehog antagonist – cancer
ARQ	solid tumors
R667	RAR gamma - emphysema
GEN	**Raptiva** - renal transplant
ISO	renal transplant
R1626	HCV pol - HCV
R3484	HPV16 – cervical neoplasia
R1439	**aleglitazar** – type 2 diabetes
R1579	DPP-IV (3) – type 2 diabetes
R1583	GLP1 - type 2 diabetes
R1594	**ocrelizumab** – RRMS
R1678	schizophrenia
R3487	Alzheimer's / schizophrenia
R744	**CERA** – chemo induced anaemia
CHU	gastroparesis / IBS

phase III - (4 NMEs + 38 AIs)

R105	**MabThera** – CLL 1st line
R105	**MabThera** – CLL relapsed
R105	**MabThera** – iNHL maint. 1st line
R105	**MabThera + Avastin** – NHL aggr.
R340	**Xeloda** - adj. CC combo oxaliplatin
R340	**Xeloda** – adj. CC combo Avastin
R340	**Xeloda** – adj. BC
R435	**Avastin** - adj. CC
R435	**Avastin** – prostate cancer
R435	**Avastin** – adj mBC HER2+
R435	**Avastin** – ovarian cancer 1st line
R435	**Avastin**–mBC combo std. chem. 1st l.
R435	**Avastin** – mBC combo Hercept. 1st. l.
R435	**Avastin** – adj. NSCLC
R435	**Avastin** – met. gastric cancer
R435	**Avastin** – adj. BC HER2-
R597	**Herceptin** –m. gastric cancer HER2+
R1273	**pertuzumab** – mBC Her2+
R1415	**Tarceva** – NSCLC maint 1st line
R1415	**Tarceva** – adj. NSCLC
R1415+R435	**Tarceva+Avastin**–NSCLC maint.1st l.
R1415+R435	**Tarceva + Avastin** – NSCLC 2nd line
GEN	**Avastin** – ovarian cancer 2nd line
GEN	**Avastin** – GIST recurr.
GEN	**Avastin** – adj. rectal cancer
GEN	**Avastin** – mBC 2nd line
GEN	**Avastin** – high risk carcinoid
R99	**CellCept** – pemphigus vulgaris
R105	**MabThera** – RA DMARD IR
R1569	**Actemra** – sJIA
R1594	**ocrelizumab** – RA Signs & sympt.
R1594	**ocrelizumab** – LN
CHU	**ED-71** – osteoporosis
GEN	**MabThera** – lupus nephritis
GEN	**MabThera** – ANCA ass. vascul.
GEN	**Xolair** – pediatric asthma
R127	**Valcyte** – CMV extension
R1658 [1]	CETP inh. - dyslipidemia
GEN	**TNKase** – catheter clearance
GEN	**Lucentis** – diabetic macular edema
GEN	**Lucentis** – retinal vein occlusion
CHU	**Epogin** – chemo induced anaemia

Registration - (2 NMEs + 4 AIs)

R340	**Xeloda** – mCRC combo 1st line
R340	**Xeloda**–mCRC combo 2nd line
R435 [1]	**Avastin** – RCC
R435	**Avastin** – mBC combo Taxotere
R1569	**Actemra** - RA
CHU	**Antevas** – subarach. haemorr.

[1] Approved in EU, US to file in 2008

NME

Additional Indication

DBA Oncology
DBA Inflammation
DBA Virology
DBA Metabolic
DBA CNS
Others

R-No.	**Roche managed**
GEN	**Genentech managed**
CHU	**Chugai managed**
ARQ	**ArQule opt-in**
BTI	**BioTie opt-in**
ISO	**Isotechnika opt-in**

Status as of June 30, 2008

Roche managed R&D pipeline - overview

Projects by Disease Biology Area (DBA)



89 Projects



85 Projects
Including 4 in phase 0

Status as of June 30, 2008

Major Roche managed projected submissions

over the next years



Phase 3

- **2008**
  - **Avastin** mBC + docetaxel (EU)
  - **Avastin** glioblastoma 2nd line (EU)
  - **MabThera** CLL (EU)
  - **Tarceva+Avastin** NSCLC 2nd line (EU)
- **2009**
  - **Avastin** mBC + standard chem (EU)
  - **Herceptin** gastric Ca (EU)
  - **Tarceva** NSCLC 1st line maint (EU)
  - **Tarceva + Avastin** NSCLC 1st line maint (EU)
  - **Xeloda** adj BC
  - **Xeloda** adj CC combo oxaliplatin
  - **MabThera** RA DMARD IR and JPD (EU)
- **2010**
  - **Avastin** adj CC (EU)
  - **Avastin** gastric Ca metastatic (EU)
  - **Avastin** ovarian Ca (EU)
  - **Xeloda+Avastin** adj CC (EU)
  - **ocrelizumab (R1594)** RA S & S + LN (EU)
- **2011**
  - **Avastin** prostate Ca (EU)
  - **Avastin+Herceptin** mBC 1st line (EU)
  - **MabThera** iNHL maint 1st line (EU)
  - **pertuzumab (R1273)** HER 2+ mBC (EU)
  - **ocrelizumab (R1594)** RA PJD (EU)
- **post 2011**
  - **Avastin** adj mBC Her 2+(EU)
  - **Avastin** adj NSCLC (EU)
  - **Avastin** HER2- adj BC (EU)
  - **MabThera+Avastin** aggressive NHL (EU)
  - **Tarceva** adj NSCLC (EU)
  - **CETP inh (R1658)** dyslipidemia

Phase 2

- **2010**
  - **GLP-1(R1583)** type II diabetes
- **2011**
  - **HCV pol inh (R1626)** HCV
  - **aleglitazar (R1439)** type II diabetes
- **post 2011**
  - **Avastin** glioblastoma 1st line (EU)
  - **Avastin** NSCLC squamous (EU)
  - **IGF-1R inh huMAb(R1507)** Ewing's sarcoma
  - **pertuzumab (R1273)** early BC (EU)
  - **Tarceva+Avastin** NSCLC 1st line (EU)
  - **TDM1 (R3502)** mBC (EU)
  - **RAR gamma (R667)** emphysema
  - **HPV 16 (R3484)** cervical neoplasia
  - **Alpha7 nic ago (R3487)** AD / schizophrenia
  - **GlyT1 inh (R1678)** schizophrenia
  - **CERA (R744)** cancer anaemia

🟧 DBA Oncology
🟪 DBA Inflammation
🟥 DBA Virology
🟦 DBA Metabolic
🟨 DBA CNS
⬜ Others

Unless stated otherwise, submissions will occur in US and EU

Status as of June 30, 2008

H1 2008: Diagnostics sales by region

Above market growth in all regions, particularly in Japan and emerging markets

CHF 4,747 m



local sales growth



* Europe, Middle East and Africa

Tissue Diagnostics sales consolidated since beginning of February 2008

Applied Science

Growth triple the Life Science market



- Strong growth in sequencing despite increased competition
  - system updates enabling broader research applications
- Updates to LightCycler 480 system strengthens leading position in genomics
- Expanded NimbleGen microarray menu to over 40 high-density arrays

all growth in local currencies

Molecular Diagnostics

Growing core business, preparing new markets



- Launched new Chlamydia test in Europe
- Japanese Red Cross transitioned to automated multiplex HIV, HCV, HBV test
- Initiated new HPV study to support FDA registration
- Exclusive distribution agreement with DxS Ltd for tests for K-RAS and EGFR mutations
- Automated HCV viral load test and multiplex HIV, HCV, HBV blood screening test pending FDA review

all growth in local currencies

Professional Diagnostics

Double-digit increase in Immunochemistry sales in all regions



- Strong demand for cobas 6000 driving market gains in Immunochemistry
- Six new immunoassays launched exUS:
  - HCV (hepatitis C Virus) antibody test
  - Procalcitonin (sepsis)
  - anti-TSH receptor antibodies, the first fully-automated assay on the market
  - Anti-CCP immunoassay (Rheumatoid Arthritis)
- POC fuelled by increased uptake Cardiac proBNP assay and CoaguChek XS monitor for coagulation monitoring

all growth in local currencies

Tissue Diagnostics

Integration on plan; maintained market out-performance

Ventana sales on a stand-alone basis



- Continued high growth in Advanced Staining (IHC, ISH) - both reagents and instruments
- Launched Vantage, first complete workflow management system designed to improve productivity and patient safety for anatomical pathology
- Symphony system enhancements released in US to accelerate penetration in Primary Staining
- Launched imaging application for the *HER-2* SISH (VIAS) in EU

all growth in local currencies

Diabetes Care

New products restoring growth



- North America Q2 sales grew strongly following weak Q1
- Accu-Chek Aviva main driver with strong double–digit growth
- Launched Accu-Chek Compact Plus in US and Japan in Q2
- Strong growth from emerging markets
- Infusion systems flat

all growth in local currencies

* growth Q2 '08 vs. Q2 '07

H1 2008: Diagnostics Division local sales

By Region and Business Area (vs. 2007)

Sales CHF m	Global	% loc growth	North Am.	% loc growth	EMEA	% loc growth	RoW	% loc growth
Professional Diag.	2,183	9	412	8	1,302	6	469	20
Diabetes Care	1,482	2	347	-7	925	5	210	11
Molecular Diagnostics	551	4	173	2	238	1	140	10
Applied Science	367	21	147	31	156	11	64	23
Tissue Diagnostics[1]	164	-	113	-	41	-	10	-
Diagnostics Division	**4,747**	**11**	**1,192**	**15**	**2,662**	**7**	**893**	**18**

[1] sales from beginning of February 2008

Diagnostics Division quarterly sales and local growth[1]

Sales CHF m	Q1 '07	% loc	Q2 '07	% loc	Q3 '07	% loc	Q4 '07	% loc	Q1 '08	% loc	Q2 '08	% loc
Professional Diagnostics	1,017	5%	1,093	8%	1,047	7%	1,137	10%	1,070	10%	1,113	9%
Diabetes Care	755	11%	789	3%	768	0%	904	7%	699	-3%	783	7%
Molecular Diagnostics	278	-2%	296	-3%	282	-3%	292	1%	270	4%	281	3%
Applied Science	166	7%	165	12%	167	11%	194	15%	183	19%	184	23%
Tissue Diagnostics									65	n.a.	99	n.a.
DIA Division	**2,216**	**6%**	**2,343**	**5%**	**2,264**	**4%**	**2,527**	**8%**	**2,287**	**9%**	**2,460**	**13%**

[1] 2007 vs. 2006 for Q1 to Q4 '07, 2008 vs. 2007 for Q1 to Q2 '08

2008: Key planned product launches* (1)

Product	BA[1]	Indication	Region
cobas 4000 analyzer series - **cobas** c 311 analyzer	PD	Next generation system consolidating clinical chemistry and immunochemistry testing for small to medium workload laboratories; software links stand-alone **cobas c** 311 analyzer (clinical chemistry) & **cobas e** 411 analyzer (immunochemistry) modules with **cobas p** 242 data manager	Global
Accu-Chek Inform II system	PD	First wireless enabled hospital blood glucose meter	Global
Immunochemistry menu	PD	New assays for a number of important diagnostic uses: •Elecsys Anti-HCV: Assay for the detection of hepatitis C infection •Elecsys anti-CCP (anti-cyclic citrullinated peptide antibody),: Assay for the diagnosis of rheumatoid arthritis •IL-6 (interleukin-6): Immunoassay to aid in management of critically ill patients as early indicator for acute inflammation and to monitor course of disease •Procalcitonin: immunoassay to aid in early detection and monitoring of sepsis •Elecsys Anti-CMV IgG and Anti-CMV IgM: For the detection of cytomegalovirus infection	Global/ EU

[1] Business Areas: Professional Diagnostics (PD)

* Subject to appropriate regulatory approvals; US launches may be later than indicated

---

2008: Key planned product launches* (2)

Product	BA[1]	Indication	Region
Cobas TaqMan 48 HBV Test	MD	Automated, real-time PCR test for monitoring hepatitis B viral load	US
Cobas AmpliPrep/ Cobas TaqMan HCV Test	MD	Real-time PCR quantification of HCV viral levels on fully automated Cobas AmpliPrep/Cobas TaqMan systems	US
cobas TaqScreen MPX Test	MD	Screens donated blood for major viruses (HIV-1, HIV-2, hepatitis B, and hepatitis C) in a single assay . Will run on automated cobas s 201 system in US and on automated, fully integrated cobas s 401 system in Japan	US, Japan
Cobas TaqMan 48 CT Test	MD	New version of an automated, real-time PCR test for Chlamydia trachomatis; also detects the new Swedish CT strain	EU
Accu-Chek Aviva Nano	DC	Enhanced portability by reduced size, combined with an attractive design and improved features	Global
Accu-Chek Active (new)	DC	Proven performance with additional features in a handy modern design	Global
XLR-HD	AS	DNA sequencing kit enabling increased read lengths and higher throughputs per plate (454)	Global

[1] Business Areas: Applied Science (AS), Molecular Diagnostics (MD), Diabetes Care (DC)

* Subject to appropriate regulatory approvals; US launches may be later than indicated

2008: Key planned product launches* (3)

Product	BA[1]	Indication	Region
BenchMark™ ULTRA	TD	Continuous access, patient case-centric IHC/ISH staining system to enhance laboratory workflow	Global
CONFIRM® anti-EGFR (5B7) Primary Antibody	TD	Proprietary rabbit monoclonal antibody with potential applications as a Prognostic or Companion Diagnostic	Global
*ultra*VIEW™ Red ISH for two color Detection Kit	TD	Companion to the *ultra*VIEW™ SISH detection kit to provide single slide, two parameter detection	Global
VANTAGE™ Information Solution	TD	Workflow solution for productivity improvement through lean processes and positive sample tracking throughout the laboratory	US

[1] Business Areas: Tissue Diagnostics (TD)

* Subject to appropriate regulatory approvals; US launches may be later than indicated

---

Group operating profit[1] H1 2008



[1] before exceptional items [2] at constant exchange rates



Equity 30 June 2008

Decrease due to dividend, currency translation adjustments and change in ownership of Ventana and Chugai

[1] mainly currency translation adjustments



Balance sheet

84% long-term financing, substantial fx effects

2008 and 2007

Average exchange rates against CHF

	H1 '08	H1 '07
EUR	1.61	1.63
USD	1.05	1.23
JPY	1.00	1.02



Exchange rate impact on sales growth

Significant negative impact from weaker USD





2008 and 2007

CHF / USD



2008 and 2007

CHF / EUR